Literature DB >> 18773254

The pattern and clinical manifestations of rheumatoid arthritis in Sarawak General Hospital.

C L Teh1, J S Wong.   

Abstract

The aim of our study is to describe the pattern, clinical features, treatment regimes, and disease activity among the patients treated for rheumatoid arthritis (RA) in the Sarawak General Hospital. We performed a cross-sectional study of all patients with a diagnosis of RA who received treatment at the General Medical Clinic and the Rheumatology Clinic in Sarawak General Hospital over a 1-year period from 1st June 2006 to 31st May 2007. Demographic data, clinical features, and disease activity of all 154 patients were collected for statistical analysis. Rheumatoid arthritis afflicts all the major racial groups in Sarawak including the native population. Our patients have a mean disease duration of 5.4 years (SD 5.69) and a mean duration of delay in diagnosis RA and initiation of disease-modifying antirheumatic drug (DMARD) treatment of 42.9 months (SD 60.1). They have a low rate of interstitial lung disease (6.5%) and rheumatoid nodules (4.5%). Rheumatoid factor was positive in 65.5% of our patients. They have a mean Disease Activity Score (DAS) 28 score of 4.28 (SD 1.33). Only 12.5% of our patients are in remission with DAS 28 < 2.6 and 30.9% of our patients are having high disease activity with DAS 28 > 5.1. Despite the high usage of DMARDs in Sarawak (>80%), our patients have severe disease with high disease activity indices. This is most likely due to delay in diagnosis and initiating DMARDs in RA patients in Sarawak.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18773254     DOI: 10.1007/s10067-008-0945-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  16 in total

1.  Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.

Authors:  Tuulikki Sokka; Theodore Pincus
Journal:  J Rheumatol       Date:  2002-12       Impact factor: 4.666

2.  Methotrexate is the leading DMARD in Finland.

Authors:  T Klaukka; K Kaarela
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

3.  HLA-DRB1 genes and susceptibility to rheumatoid arthritis in three ethnic groups from Malaysia.

Authors:  K F Kong; S S Yeap; S K Chow; Maude E Phipps
Journal:  Autoimmunity       Date:  2002-07       Impact factor: 2.815

4.  Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study.

Authors:  E Tsakonas; A A Fitzgerald; M A Fitzcharles; A Cividino; J C Thorne; A M'Seffar; L Joseph; C Bombardier; J M Esdaile
Journal:  J Rheumatol       Date:  2000-03       Impact factor: 4.666

5.  Pattern of rheumatoid arthritis in West Malaysia.

Authors:  B H Toh; S Sengupta; A H Ang; J C White; K S Lau
Journal:  Ann Rheum Dis       Date:  1973-03       Impact factor: 19.103

6.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

7.  Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996.

Authors:  M M Ward; J F Fries
Journal:  J Rheumatol       Date:  1998-03       Impact factor: 4.666

8.  Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

Authors:  Timo Möttönen; Pekka Hannonen; Markku Korpela; Martti Nissilä; Hannu Kautiainen; Jorma Ilonen; Leena Laasonen; Oili Kaipiainen-Seppänen; Per Franzen; Tapani Helve; Juhani Koski; Marianne Gripenberg-Gahmberg; Riitta Myllykangas-Luosujärvi; Marjatta Leirisalo-Repo
Journal:  Arthritis Rheum       Date:  2002-04

9.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

Authors:  Catriona Grigor; Hilary Capell; Anne Stirling; Alex D McMahon; Peter Lock; Ramsay Vallance; Wilma Kincaid; Duncan Porter
Journal:  Lancet       Date:  2004 Jul 17-23       Impact factor: 79.321

10.  QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries.

Authors:  Tuulikki Sokka; Hannu Kautiainen; Sergio Toloza; Heidi Mäkinen; Suzan M M Verstappen; Merete Lund Hetland; Antonio Naranjo; Eva Baecklund; Gertraud Herborn; Rolf Rau; Massimiliano Cazzato; Laure Gossec; Vlado Skakic; Feride Gogus; Stanislaw Sierakowski; Barry Bresnihan; Peter Taylor; Catherine McClinton; Theodore Pincus
Journal:  Ann Rheum Dis       Date:  2007-04-05       Impact factor: 19.103

View more
  4 in total

1.  Impact of tight control strategy on rheumatoid arthritis in Sarawak.

Authors:  Cheng Lay Teh; Jin Shyan Wong
Journal:  Clin Rheumatol       Date:  2010-10-01       Impact factor: 2.980

Review 2.  Patterns of disease-modifying antirheumatic drug use in rheumatoid arthritis patients after 2002: a systematic review.

Authors:  Gabriela Schmajuk; Daniel H Solomon; Jinoos Yazdany
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-12       Impact factor: 4.794

3.  Estimating the prevalence and disease characteristics of rheumatoid arthritis in Tehran: A WHO -ILAR COPCORD Study (from Iran COPCORD study, Urban Study stage 1).

Authors:  Ahmad-Reza Jamshidi; Arash Tehrani Banihashemi; Shima Roknsharifi; Masoumeh Akhlaghi; Ahmad Salimzadeh; Fereydoun Davatchi
Journal:  Med J Islam Repub Iran       Date:  2014-09-14

4.  Demographic and Clinical Patterns of Rheumatoid Arthritis in an Emirati Cohort from United Arab Emirates.

Authors:  Rajaie Namas; Abhay Joshi; Zarmeena Ali; Jamal Al Saleh; Mohammed Abuzakouk
Journal:  Int J Rheumatol       Date:  2019-09-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.